Among the pioneers are the United States with its Operation Warp Speed with its futuristic sound; Europe and China also have their own leading candidate vaccines; as the race warms, the less evolved countries of Asia, Africa and South America are cheering and waiting for crumbs, where maximum clinical trials of vaccines will be performed or are already being conducted.
Typically, it takes at least 4 years to expand a vaccine before it is marketed, but at the age of COVID-19, fitness experts are positive about a vaccine in a year or less. There’s a sense of urgency and we’re waiting for penetration.
Meanwhile, in the most sensitive of the vaccine queue, which is expected to be in condition until the end of the year, are the populations of Western countries, which are, of course, the precedence of their governments that financed studies in The First Place.
The global emergence as laboratories
Poor Asian countries and the rest of those coming globally unfortunately have to wait until the end of the line, so some of them have agreed to be guinea pigs for vaccine trials in the hope that they will take precedence when vaccines become available. put in service Beggars can’t choose.
In mid-August, President Rodrigo Duterte suggested that the Philippines participate in phase 3 trials of the Russian Sputnik vaccine against Saudi Arabia and the United Arab Emirates to enroll the Philippines in clinical trials. The Russian offer of clinical trials in the country can be a catastrophic mistake because Russian assignment is suspicious.
Indonesia has begun a complex human trial of a CoVID-19 vaccine manufactured in China involving up to 1,620 patients. No less than Indonesian President Joko Widodo presented the essay at a rite in Bandung, West Java, in mid-August.
Indonesia’s resolve to be a spouse of China in clinical trials may be a major gamble, as China is a career leader in producing a vaccine.
The candidate vaccine produced through Sinovac Biotech is among the few in the world to participate in phase 3 clinical trials, or large-scale human trials, the last step before regulatory approval. Bangladesh too.
Asia is the preferred destination of drug brands for clinical trials for several reasons. These come with medical experience in areas of rapid healing, the availability of giant patient groups, laboratories and infrastructure, comparable quality and lower costs. Another thing is the occurrence and comparables. de of Western diseases.
There is also global data acceptability. Data from clinical trials in Asia are widely accepted through regulatory agencies: the US Food and Drug Administration is widely accepted. (USFDA) and the European Medicines Agency (EMA). In addition, the prices of procedures, diagnostic tests and visits to Asia are 30-40%. decline than in the United States and Europe.
Science will have to succeed over politics
As the race heats up, a warning is needed: scientists will have to not sacrifice clinical integrity for policies, but they will have to stick to strict protocols for clinical studies and production. Governments want to put science into politics in the vaccine race.
Safety and efficacy are related to vaccine progression. An error in clinical trials caused by hasty procedures, for example, can result in deaths that will delay studies and progression over several years.
As things are, there are already “doubts about vaccines” among the public everywhere, especially among the uninformed. Surveys show that U. S. citizens have less self-confidence in protecting vaccines.
A survey conducted through the opinion and knowledge company YouGov in May found that 55% of U. S. adults said they would get a COVID-19 vaccine. By the end of July, that figure had fallen to 41 cents well below 60 to 70 in line with the penny that experts will need to download “collective immunity. “
There is also significant skepticism about vaccines in other countries, according to a recent Wellcome Trust study. In France, less than part of other people think vaccines are safe. In Ukraine, the most skeptical country in the world, the figure is only 29%. . Do not feed this vaccine with faults.
Who are the first vaccines?
As superpowers rush to the end line, the rhetorical question arises: who gets the vaccines first?Rhetoric because, unless a foreign framework intervenes, we know that the deficient will have the final say. Some countries in Asia and Africa have negotiated agreements, but not the maximum in Asia and Africa. And even for those who have negotiated agreements, there is no guarantee, and whether the amount of dose to be received will be sufficient to cover the majority of the population.
Unless governments partially or completely subside vaccines, they will be unaffordable to the poor. Early reports imply that Chinese vaccines will charge $145 according to injection into the open market, while those in Oxford, UK, will charge only $4 to $10, as some countries plan to provide loose vaccines, and even pay others to deal with herd immunity, about 70 to 90% of the population.
There is hope on the horizon through COVAX, a consortium of 172 economies that is being organized and is working with vaccine brands to provide countries around the world with equitable access and effective vaccines once authorized and approved. to work with governments and brands to make sure COVID-19 vaccines are available worldwide for high- and low-income countries,” organizers said in a press release.
Richard Hatchett, executive director of the Coalition for Epidemic Preparedness Innovations, one of COVAX’s organizers, says: “In the race to locate a vaccine, countries can . . . join to participate in an initiative founded on enlightened self-interest and also equity, without leaving any country behind. “